Form 4: LeMaitre Vascular CEO Reports Routine Stock Transactions

LeMaitre Vascular's Chairman and CEO, George W. LeMaitre, reported the acquisition of 45 shares and disposition of 455 shares of common stock on December 2, 2025, primarily related to RSU vesting and tax obligations.

Summary

• George W. LeMaitre, Chairman and CEO of LeMaitre Vascular Inc. (LMAT), reported transactions involving the company's common stock.
• On December 2, 2025, 45 shares of common stock were acquired upon the release of dividend equivalent rights, on a one-for-one basis, with a transaction price of $0.
• Concurrently, 455 shares of common stock were disposed of at a price of $83.68 per share to satisfy tax withholding obligations.
• These disposed shares were related to the vesting of restricted stock units (RSUs) awarded to Mr. LeMaitre on December 2, 2020.
• The disposition for tax withholding is considered an exempt sale pursuant to Rule 16b-3(e) of the Securities Exchange Act of 1934.
• Following these transactions, Mr. LeMaitre directly beneficially owns 1,665,574 shares of common stock.
• An additional 21,300 shares are indirectly held by the LEMAITRE IRREVOCABLE LIFE INSURANCE TRUST OF 2025, for which Mr. LeMaitre disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The filing is neutral as it reports routine insider transactions related to executive compensation (vesting and tax withholding) and does not indicate any significant strategic shifts or unexpected financial events.

Positives

• The vesting of restricted stock units (RSUs) and the release of dividend equivalent rights indicate the fulfillment of compensation incentives for the Chairman and CEO.

Negatives

• The disposition of 455 shares of common stock reduces the direct beneficial ownership of the Chairman and CEO, although this was for tax withholding purposes.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing details routine insider transactions related to executive compensation, which is a standard practice across publicly traded companies in all industries, including the medical device sector where LeMaitre Vascular operates. It does not provide specific insights into broader industry trends or competitive positioning.

Comparison to Industry Standards

• The vesting of restricted stock units and subsequent share disposition for tax withholding are common components of executive compensation packages across various industries, aligning with typical corporate governance practices for incentivizing and retaining key management.
• The use of an irrevocable trust for indirect shareholding is also a common estate planning and wealth management strategy among executives, similar to practices observed in comparable companies within the medical technology sector.

Related Party Transactions

• 21,300 shares of common stock are held indirectly by the LEMAITRE IRREVOCABLE LIFE INSURANCE TRUST OF 2025, which benefits the reporting person's child(ren). The reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.

Stakeholder Impact

• Shareholders: The impact is minimal as these are routine insider transactions related to executive compensation and tax obligations, not indicative of a change in management's confidence or company fundamentals.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Keywords

LMAT, LeMaitre Vascular, Form 4, Insider Transaction, CEO, Director, Common Stock, Dividend Equivalent Rights, Restricted Stock Units, Tax Withholding